IP Library Granted Patent US 8,729,239
Granted Patent B2
US 8,729,239 · App. 13/258,666 · Granted May 20, 2014

Antibodies against fatty acid synthase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,729,239
App. No.
13/258,666
Granted
May 20, 2014
Kind
B2
Abstract

The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.

Claims (9)

1. An isolated monoclonal antibody that specifically binds to the amino acid sequence of SEQ ID NO. 4.

2. The monoclonal antibody of claim 1 which is human or humanized.

3. A monoclonal antibody obtained by a method comprising the steps of:

a. contacting a mammal with the peptide consisting of SEQ ID NO. 4;

b. collecting cells containing the antibody from the mammal; and

c. immortalizing the cells obtained in step (b) thereby creating a hybridoma expressing the monoclonal antibodies that specifically bind to the amino acid sequence of SEQ ID NO. 4.

4. The monoclonal antibody of claim 3 wherein the mammal is immuno-compromised and the monoclonal antibody produced is a human antibody.

5. A method for detecting the presence or amount of a FAS protein or polypeptide in a biological sample comprising contacting the sample with the monoclonal antibody of any one claims 1 - 3 , and determining the amount of the FAS protein bound to the monoclonal antibody.

6. The method of claim 5 wherein the monoclonal antibody is labeled with a detectable label.

Assignments (2)
COURT ORDER Recorded Jun 1, 2017
From: NUCLEA BIOTECHNOLOGIES, INC.
To: NMDX, LLC
Reel/Frame 042562/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2011
From: MURACA, PATRICK J.
To: NUCLEA BIOTECHNOLOGIES, INC.
Reel/Frame 027053/0199 →